Physician profile
Reinaldo Ramirez Amill
NPI 1538571419
$2,958.48
in general payments reported to CMS, 2019-2025
15 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $53.62 · 2021: $388 · 2022: $339 · 2023: $498 · 2024: $365 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,147.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $332.70 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $223.04 | 2019 | |
| Janssen Scientific Affairs, LLC | $216.11 | 2019 | |
| Gilead Sciences, INC. | $206.06 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $148.17 | 2019-2024 | Stelara |
| Eisai INC. | $125.00 | 2019 | |
| Pbg Puerto Rico LLC | $108.18 | 2019-2021 | |
| Janssen Biotech, INC. | $99.95 | 2021 | |
| Boston Scientific Corporation | $98.78 | 2019 | |
| Lilly USA, LLC | $85.00 | 2024 | Omvoh |
| Olympus Latin America, INC. | $83.77 | 2019 | |
| Organon LLC | $37.84 | 2022-2023 | Hadlima, Renflexis |
| Pfizer Pharmaceuticals LLC | $25.23 | 2019 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $21.40 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reinaldo Ramirez Amill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.